Four Fab 5% Yielders! AstraZeneca plc, Standard Life Plc, eSure Group PLC & Vodafone Group plc

Royston Wild discusses the dividend prospects of AstraZeneca plc (LON: AZN), Standard Life Plc (LON: SL), eSure Group PLC (LON: ESUR) and Vodafone Group plc (LON: VOD).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I’m running the rule over four FTSE-quoted dividend giants.

Global greatness

With earnings expected to explode this year and beyond, I reckon dividend hunters should give insurance star Standard Life (LSE: SL) more than a passing glance.

The business is rapidly expanding overseas to underpin future profits growth, a strategy that helped net inflows to more than double in 2015 to £12.6bn. Indeed, more than two-thirds of these inflows came from outside the UK.

With Standard Life’s leading position in the fast-growing savings and pensions markets paying off handsomely, a dividend of 18.36p per share in 2015 is expected to rise to 19.7p this year, and again to 21.2p in 2017. Consequently the insurer carries market-smashing yields of 5.4% and 5.8% for these years.

Motoring higher

Diversified insurer Esure (LSE: ESUR) is well placed to enjoy the end of the low-premium era, in my opinion. A backdrop of rising policy costs underpinned a 30% uptick in pre-tax profits last year, to £134m, and further hefty gains would appear to be on the cards.

Gross written premiums advanced 6.3% in 2015, and Esure expects premiums to advance between 10% and 15% in the current period. As well as benefitting from rising prices, Esure is also growing its customer base in the critical Motor segment.

The business was forced to cut the dividend in 2015 to build its capital pile, reducing the payment to 11.5p per share from 16.8p the previous year.

But with market conditions steadily improving, the City has chalked-in dividends of 13.2p for 2016 and 15.5p for next year. These figures create gigantic yields of 4.9% and 5.8%, respectively.

A mobile master

Telecoms titan Vodafone’s (LSE: VOD) heavy spending of recent years continues to deliver stonking returns. The company has thrown vast amounts into improving its data and voice capabilities, moves that have steadily improved its performance in its critical European marketplaces.

Vodafone’s Project Spring organic investment scheme has also enabled it to take advantage of surging demand across Asia, the Middle East and Africa. And sales from these regions should keep galloping amid exploding population growth and rising income levels.

With earnings expected to start moving higher again from next year, Vodafone is expected to fork out dividends of 11.5p per share for the periods concluding March 2016 and 2017, respectively, yielding a handsome 5.3%.

In good health

I believe the dependable nature of medicines demand should power earnings — and consequently dividends — at pharma giant AstraZeneca (LSE: AZN) through the roof in the coming years.

Sure, the issue of patent losses on key labels is set to remain an anchor around the bottom line for some time yet — the City expects AstraZeneca to rack up further bottom-line slides in 2016 and 2017.

But AstraZeneca is pulling out all the stops to offset these losses, culminating in a 21% hike in R&D spend in 2015 alone. A subsequent improvement in the firm’s product pipeline should provide ample rewards as healthcare spend explodes across the globe, in my opinion.

The dividend is expected to remain locked at 280 US cents through to the close of next year. But this still yields a handsome 4.8%, and I expect this figure to march higher again in the years ahead as profits advance.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

5 steps to start buying shares with under £500

Learn how this writer would start buying shares with a few hundred pounds in a handful of steps, if he…

Read more »

Young happy white woman loading groceries into the back of her car
Investing Articles

The FTSE 100 offers some great bargains. Is this one?

Our writer digs into one FTSE 100 share that has had a rough 2024 to date, ahead of its interim…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£9,000 of savings? Here’s my 3-step approach to aim for £1,794 in passive income

Christopher Ruane walks through the practical steps he would take to try and turn £9,000 into a sizeable passive income…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

I’d buy 29,412 shares of this UK dividend stock for £150 a month in passive income

Insiders have been buying this dividend stock, which offers an 8.5% yield. Roland Head explains why he’d choose the shares…

Read more »

Red briefcase with the words Budget HM Treasury embossed in gold
Investing Articles

Could the new UK budget spell growth for these 6 FTSE stocks? I think so!

Mark David Hartley considers six UK stocks that could enjoy growth off the back of new measures announced in the…

Read more »

Investing Articles

With a 6.6% yield, is now the right time to add this income stock to my ISA?

Our writer’s looking to boost his Stocks and Shares ISA. With this in mind, he’s debating whether to buy a…

Read more »

Dividend Shares

This blue-chip FTSE stock just fell 12.5% in a day. Is it time to consider buying?

Smith & Nephew is a well-known, blue-chip FTSE stock with a decent dividend yield. And its share price just dropped…

Read more »

Investing Articles

At 72p, the Vodafone share price looks to be at least 33% undervalued to me

Our writer looks at a number of valuation measures to determine whether the Vodafone share price reflects the fair value…

Read more »